Due Diligence Flashcards

1
Q

What is due diligence?

A

A comprehensive evaluation conducted before investing in, acquiring, or licensing a company/project.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why is due diligence important?

A

Ensures investors, companies, and stakeholders make informed decisions based on scientific, financial, legal, and operational data.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the two main types of due diligence?

A
  1. Buying a Company or Licensing a Project – Internal check on scientific assumptions & asset value.
  2. Investing in or Creating a Company – Internal & external evaluation to confirm valuation & risk.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 4 Pillars (4 P’s) of Due Diligence?

A
  1. People – Team, leadership, expertise, culture.
  2. Performance – Financials, revenue, historical data.
  3. Philosophy – Business model, core strategy.
  4. Process – Governance, operational frameworks.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the Death Valley concept in therapeutics?

A

High probability of failure before revenue generation, requiring milestone-driven funding to survive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are key funding milestones for startups?

A
  1. Preclinical toxicology data.
  2. Clinical trial results (Phase 1–3).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the difference between Milestones & Tollgates?

A

Milestones – Achievements that indicate progress (e.g., PoC data).
Tollgates – Go/no-go decision points based on key risks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are key value-adding steps in drug development?

A
  1. Pre-Company Formation – Identify promising scientific research.
  2. Company Formation – Patent filings, seed funding.
  3. Preclinical Development – PoC data in animals, lead optimisation.
  4. Clinical Development – Phase 1 safety, Phase 2 efficacy.
  5. Commercialization – Licensing deals, market access.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What factors truly add value in biotech?

A
  1. Validation of disease targets.
  2. Optimized chemistry & lead identification.
  3. Clinical proof-of-concept (PoC).
  4. Regulatory approvals (e.g., FDA IND).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the funding stages in biotech?

A
  1. Pre-Seed – Early-stage grants (£<1M).
  2. Seed – Company formation (£1M–£5M).
  3. Series A – Preclinical to early clinical (£10M–£50M).
  4. Series B/C – Late-stage clinical trials (£50M–£200M).
  5. IPO/Exit – Public market funding or acquisition (£200M+).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What do venture capitalists (VCs) expect?

A

3x–10x ROI within 10–12 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are key focus areas for investors?

A
  1. Team quality.
  2. IP protection.
  3. Regulatory progress.
  4. Competitive landscape.
  5. Exit strategy (IPO, M&A, licensing).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is Scientific & Clinical Due Diligence?

A
  1. Scientific backing (peer-reviewed data).
  2. Key milestones (target engagement, animal efficacy, Phase 1 safety).
  3. Differentiators (comparator data, unique MoA).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is People Due Diligence?

A
  1. Does the team have the right skills?
  2. Are there leadership gaps?
  3. Are investors aligned with the company vision?
  4. Is the board composition strong?
  5. Are key hires planned?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is Commercial Due Diligence?

A
  1. Competitor landscape.
  2. Revenue potential.
  3. Partnerships in place.
  4. Potential acquirers or licensees.
  5. Estimated valuation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is Legal & Governance Due Diligence?

A
  1. Are contracts in place?
  2. Is the company compliant with GDPR?
  3. Does the company have board oversight?
  4. Are employment contracts structured correctly?
17
Q

What is Financial Due Diligence?

A
  1. Company cash position.
  2. Liabilities.
  3. Expected runway before additional funding.
  4. Tax efficiency (EIS, R&D tax credits).
18
Q

What is IP Due Diligence?

A
  1. Patent protection, trade secrets, licenses.
  2. Freedom to Operate (FTO).
  3. Protection from competitors.
  4. Proper assignment of IP rights.
19
Q

How is valuation calculated?

A

Pre-Money Valuation: £5M + Investment Raised: £5M = Post-Money Valuation: £10M.

20
Q

What are common investment terms?

A
  1. Vesting (4 years).
  2. Anti-dilution protections.
  3. Restrictive covenants.
  4. Preferred shares.
  5. Liquidation preferences.
  6. Warrants & Convertible Notes.
21
Q

What are the top reasons for investor rejection?

A
  1. Valuation misalignment.
  2. Lifestyle business (not VC-fundable).
  3. Difficult founders (poor communication, unrealistic expectations).
  4. Lack of preparedness (no clear milestones/strategy).
22
Q

What are key daily activities of a VC?

A
  1. Reviewing portfolio updates.
  2. Evaluating new investment pitches.
  3. Conducting due diligence.
  4. Networking with other investors.
  5. Attending board meetings.
  6. Tracking market trends & competitors.
23
Q

What are the 5 key lessons from due diligence?

A
  1. Due diligence reduces risk & validates investments.
  2. Startups need strong scientific, financial, and legal prep.
  3. Investors focus on leadership, IP, and exit strategy.
  4. Milestone-driven funding is crucial.
  5. Investor-founder alignment is key for success.